Xu Zhang

发表

The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation.

M. Solh, D. Speckhart, S. Solomon, 2020, Blood advances.

Selecting the Best Donor for Haploidentical Transplant: Impact of HLA, Killer Cell Immunoglobulin-Like Receptor Genotyping, and Other Clinical Variables.

M. Solh, S. Solomon, A. Bashey, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy.

S. Solomon, B. Smith, S. Gore, 2015, Clinical Lymphoma, Myeloma & Leukemia.

Lineage-Specific Relapse Prediction Following Haploidentical Transplant with Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand.

M. Solh, S. Solomon, A. Bashey, 2022, Transplantation and cellular therapy.

Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide.

M. Solh, S. Solomon, A. Bashey, 2020, Blood advances.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma

Xu Zhang, Xiaojuan Gao, Tong Su, 2022, Cancer management and research.

CMAR_A_379911 3037..3046

Xu Zhang, Xiaojuan Gao, Tong Su, 2022 .

Comparison of outcomes following transplantation with T-replete HLA-haploidentical donors using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older

M. Solh, S. Solomon, A. Bashey, 2018, Bone Marrow Transplantation.

Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.

S. Solomon, A. Bashey, L. Morris, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation.

S. Solomon, A. Bashey, L. Morris, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Inferences for current chronic graft-versus-host-disease free and relapse free survival

S. Solomon, Xu Zhang, Connie A. Sizemore, 2022, BMC Medical Research Methodology.

Safety and efficacy of rituximab-based first line treatment of chronic GVHD

M. Solh, S. Solomon, A. Bashey, 2018, Bone Marrow Transplantation.

A Phase II Trial of Melphalan Based Reduced-Intensity Conditioning for Transplantation of T-Replete HLA-Haploidentical Peripheral Blood Stem Cells with Posttransplant Cyclophosphamide in Patients with Hematologic Malignancies

M. Solh, S. Solomon, A. Bashey, 2021, Advances in hematology.

Who is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidenitcal Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?

M. Solh, S. Solomon, A. Bashey, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.

S. Solomon, A. Bashey, L. Morris, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.

S. Solomon, A. Bashey, L. Morris, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine).

M. Solh, S. Solomon, A. Bashey, 2020, Leukemia research.

Pre-Transplant Platelet Refractoriness and Alternative Donors Are Associated With Cytomegalovirus Retinitis in Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

Shunqing Wang, Xu Zhang, W. Mo, 2022, Frontiers in Cellular and Infection Microbiology.

The Potential Association of Delayed T Lymphocyte Reconstitution Within Six Months Post-Transplantation With the Risk of Cytomegalovirus Retinitis in Severe Aplastic Anemia Recipients

Shunqing Wang, Xu Zhang, W. Mo, 2022, Frontiers in Cellular and Infection Microbiology.

HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis.

H. Chu, D. Weisdorf, A. Rashidi, 2019, Blood advances.

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.

M. Solh, S. Solomon, A. Bashey, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplantation Cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk In

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes

E. Dickhaus, M. Solh, S. Solomon, 2019, Bone Marrow Transplantation.

Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients

M. Solh, S. Solomon, A. Bashey, 2018, Bone Marrow Transplantation.

Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint.

M. Solh, S. Solomon, A. Bashey, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

T Cell-Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an HLA-Matched Related or Matched Unrelated Donor Transplantation.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Haploidentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors Is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of A Prospective Phase II Trial

S. Solomon, A. Bashey, L. Morris, 2011 .

Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant.

M. Solh, S. Solomon, A. Bashey, 2020, Blood advances.

Superior Survival of Black Versus White Patients Following Post-Transplant Cyclophosphamide-Based Haploidentical Transplantation for Adults with Hematologic Malignancy.

M. Solh, S. Solomon, A. Bashey, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Myeloablative Conditioning With PBSC Grafts For T-Replete Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide Results In Universal Engraftment, Low Rates Of Gvhd, NRM and Excellent Survival Outcomes: An Analysis Of Two Consecutive Phase II Studies From a Si

Ocn, S. Jacobson, S. Solomon, 2013 .

Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.

S. Solomon, A. Bashey, L. Morris, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

TBI-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors

S. Solomon, A. Bashey, L. Morris, 2014 .

Current Graft-versus-Host Disease-Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant.

M. Solh, S. Solomon, A. Bashey, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Real-world outcomes of unselected elderly acute myeloid leukemia patients referred to a leukemia/hematopoietic cell transplant program

H. Kent Holland, M. Solh, S. Solomon, 2019, Bone Marrow Transplantation.

Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD)

M. Solh, S. Solomon, A. Bashey, 2021, Bone Marrow Transplantation.

Fludarabine and Total Body Irradiation Conditioning Prior to Ablative Haploidentical Transplantation: Long-term Safety and Efficacy.

M. Solh, S. Solomon, A. Bashey, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients

M. Solh, S. Solomon, A. Bashey, 2019, Blood.

Differences in GVHD Characteristics Between Haploidentical Transplantation Using Post-Transplant Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors.

M. Solh, S. Solomon, A. Bashey, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

NephrologyDialysis Transplantation Sera from patients with anti-GBM nephritis including Goodpasture syndrome show heterogenous reactivity to recombinant NCI domain of type IV collagen a chains

K. Tryggvason, P. Dehan, S. Reeders, 2005 .

An Effective Hematopoietic Stem Cell Mobilization Algorithm for Adding Plerixafor to G-CSF for Multiple Myeloma Patients Undergoing Autologous Transplantation

S. Solomon, A. Bashey, L. Morris, 2011 .

Non-Inferior Survival of Black Versus White Patients and Superior Outcomes for Black Females Compared to Other Race/Gender Groups Following Allogeneic Transplantation for Hematologic Malignancy: A Single Center Multivariable Analysis of 475 Allografted Patients

M. Solh, S. Solomon, A. Bashey, 2015 .

High-dose Bendamustine, Etoposide, Cytarabine and Melphalan (BeEAM) Conditioning Prior to Autologous Transplantation for Patients with Multiple Myeloma.

M. Solh, S. Solomon, A. Bashey, 2022, Transplantation and Cellular Therapy.

Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development

Xu Zhang, Huanhuan Zhang, K. Ding, 2022, Frontiers in Oncology.

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

M. Solh, S. Solomon, A. Bashey, 2019, Blood.

Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant

M. Solh, S. Solomon, A. Bashey, 2023, Blood advances.

Fevers post infusion of T-cell replete hla mismatched haploidentical hematopoietic stem cells with post-transplant cyclophosphamide: risk factors and impact on transplant outcomes

E. Dickhaus, M. Solh, S. Solomon, 2019, Bone Marrow Transplantation.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.

M. Solh, S. Solomon, A. Bashey, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome

S. Solomon, A. Bashey, L. Morris, 2012 .

Chronic GVHD Is Not Increased with the Use of PBSC Instead of Bone Marrow for T-Replete HLA-Haploidentical Transplanation Using Post-Transplant Cyclophosphamide : A Multivartiate Analysis of 116 Consecutive Transplants from a Single Center

S. Solomon, A. Bashey, L. Morris, 2014 .

Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation

M. Solh, S. Solomon, A. Bashey, 2016, Bone Marrow Transplantation.

Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors

M. Solh, S. Solomon, A. Bashey, 2023, Blood advances.